Pharmaceutical Technology

MAY 19, 2023

The US Food and Drug Administration (FDA) has approved AbbVie’s Rinvoq (upadacitinib) for patients with Crohn’s disease who do not respond to TNF blockers, a common immune suppressant treatment for the condition. The FDA nod means Rinvoq is now approved for seven indications in gastroenterology, rheumatology and dermatology.

Mayo Clinic 105

Mayo Clinic Dosage FDA Immunization 105

The FDA Law Blog

MAY 13, 2024

Gibbs & Ana Loloei & Véronique Li, Senior Medical Device Regulation Expert — FDA has long touted the use of real-world evidence ( RWE ). FDA recognizes the potential of RWE to support regulatory submissions of medical devices and to inform benefit-risk analysis of such products, while assuring patients have timely access to devices.

FDA 111

FDA Medical Records Documentation 111

The FDA Law Blog

SEPTEMBER 16, 2024

Schwartz — FDA recently published a Federal Register (FR) Notice [ Docket No. FDA-2024-N-3945 ] announcing the publication of a draft strategy document, for public comment, outlining specific actions FDA plans to take to facilitate the use of innovative manufacturing technologies.

Documentation 59

Documentation FDA Communication 59

The FDA Law Blog

OCTOBER 12, 2023

Koblitz — For years, submitting a Suitability Petition has been like screaming into a void: You’d be lucky if FDA ever responds. This has been a big problem because FDA’s inattentiveness can delay entry of certain types of ANDAs for years—often resulting in the ANDA applicant’s abandonment of the Suitability Petition.

FDA 59

FDA Dosage 59

European Pharmaceutical Review

FEBRUARY 27, 2024

The facility has been designed to meet the highest environmental sustainability standards, to help Amgen’s reach its target of carbon neutrality in all operations by 2027, the company noted. .” Amgen Ohio is nearly 300,000 ft 2 in size and will employ 400 full-time staff.

Pharmaceutical Companies 105

Pharmaceutical Companies Pharmaceutical Companies FDA 105

PharmaShots

APRIL 6, 2023

A recent study published in the January 2023 issue of Clinical Pharmacology and Therapeutics described essential characteristics of a PD biomarker for biosimilar development.

FDA 53

FDA 53

The FDA Law Blog

OCTOBER 24, 2022

355g(a), directed FDA to “establish a program to evaluate the potential use of real world evidence” both “to help to support the approval of a new indication” and “to help to support or satisfy postapproval study requirements.” The sponsor and FDA reach agreement on the study design information to be publicly disclosed.

FDA 78

FDA Labelling 78

pharmaphorum

JULY 15, 2022

The PureTech group company – which scored the first FDA and EMA approvals for a DTx for attention-deficit hyperactivity disorder (ADHD) – is developing AKL-T01 to tackle cognitive impairments that can affect people with SLE. The post Akili digital therapeutic shows promise in lupus patients appeared first on.

FDA 129

FDA 129

The FDA Law Blog

NOVEMBER 22, 2023

Earlier this month, FDA issued a proposed rule that would revoke 21 C.F.R. §  180.30 , its interim authorization of the use of brominated vegetable oil (BVO) in in fruit-flavored beverages. BVO has been used as a flavoring oil stabilizer and emulsifier since the 1920s, and it was generally recognized as safe (GRAS) for this use by FDA.

FDA 52

FDA 52

pharmaphorum

MARCH 21, 2022

Shares in Provention Bio cratered last July when the FDA turned down its marketing application for type 1 diabetes therapy teplizumab. But armed with new data it has tried again, with the FDA due to make a decision on the new filing by 17 August.

FDA 52

FDA 52

pharmaphorum

NOVEMBER 18, 2022

At its second attempt, Provention Bio has secured FDA approval for teplizumab, as a treatment to delay late-stage type 1 diabetes (T1D) in at-risk individuals – becoming the first disease-modifying therapy for these patients. It is now in line for a $35 million equity investment by Sanofi following FDA approval.

FDA 52

FDA Immunization 52

pharmaphorum

JANUARY 4, 2022

An appeals court ruling has upheld the validity of a key US patent covering Gilenya (fingolimod), and issued a permanent injunction against HEC Pharma until it expires in December 2027. Generics could still appear on the US market before the end of 2027 however.

FDA 59

FDA 59

European Pharmaceutical Review

JANUARY 10, 2023

Treatments identified in the report are predicted to be potential blockbuster drugs by 2027 or have potential to serve unmet patient needs for millions of patients worldwide. They have accounted for over 25 percent of Food and Drug Administration (FDA) approvals for the last seven years, the report found.

FDA 98

FDA 98

European Pharmaceutical Review

MAY 4, 2023

According to Research and Markets 8 , the market for bispecific antibodies for cancer is forecasted to grow by $400 million during 2022-2027, due to the increasing prevalence of cancer worldwide. They are not US Food and Drug Administration (FDA)-approved for these patients due to the lack of benefit. Personalized medicine at FDA.

Immunization 98

Immunization Chemotherapy FDA 98

The FDA Law Blog

JULY 24, 2023

After suing each other in patent litigation and Avadel’s suit against FDA challenging the Agency’s authority to compel patent certifications, it’s Jazz’s turn to sue FDA. Approximately six weeks after FDA approved Lumryz and issued its clinical superiority decision , Jazz filed a Complaint against FDA in the District Court of D.C.

FDA 52

FDA Patient Care 52

pharmaphorum

MARCH 18, 2022

Akili’s first product – EndeavorRx for treating attention deficit hyperactivity disorder (ADHD) – was the first prescription gaming app approved by the FDA. The company is developing follow-up products for other conditions, including multiple sclerosis, autism, and depression.

FDA 98

FDA 98

European Pharmaceutical Review

JANUARY 19, 2023

The additional support from Amgen is set to reach more than 300 diverse and community-oriented clinical investigators by 2027. Currently close to 80 percent of participants in clinical research trials are white, according to the Food and Drug Administration (FDA).

FDA 98

FDA 98

The FDA Law Blog

OCTOBER 6, 2023

Javitt & Philip Won — As we reported last week, FDA has issued a 26 page, single spaced, tiny-font Proposed Rule of Laboratory Developed Tests (LDTs). The brevity of this change belies the foreseeably seismic impact of FDA regulation of clinical laboratories on the healthcare system. By Allyson B. Mullen & Gail H.

FDA 64

FDA Labelling 64

The FDA Law Blog

JUNE 8, 2023

FDA has begun to reintroduce in-person meetings. It is also noteworthy that in the March 27 announcement , FDA distinguished between teleconferences and videoconferences despite using the same online platform (e.g., Applicants should also be aware that FDA has the discretion to decide the format of the meeting (e.g.,

FDA 53

FDA Communication Documentation 53

The Checkup by Singlecare

JUNE 25, 2025

One example is Breo Ellipta (fluticasone furoate/vilanterol), an inhalation powder approved by the Food and Drug Administration (FDA) as a once-daily maintenance treatment (not a rescue inhaler) for COPD and asthma. Medicare Part D beneficiaries may also save more on Breo Ellipta starting in 2027. Can you get Breo Ellipta for free?

Insurance 52

Insurance Dosage FDA 52

pharmaphorum

MAY 27, 2022

Akili’s EndeavorRx is the first FDA and EMA-approved digital therapeutic (DTx) for ADHD and is designed to target and activate neural systems by presenting sensory stimuli and motor challenges to improve cognitive functioning. .” The post Akili partners with gaming giant Roblox on ADHD therapy delivery appeared first on.

FDA 93

FDA 93

pharmaphorum

JUNE 22, 2022

Qulipta (atogepant) is already approved for prevention of episodic migraine – where attacks are less frequent – getting the green light from the FDA last September for this use a few months after Biohaven and Pfizer’s Nurtec ODT (rimegepant). The post AbbVie files Qulipta for chronic migraine prevention appeared first on.

Labelling 69

Labelling FDA 69

pharmaphorum

OCTOBER 6, 2021

The orally-active drug was granted breakthrough status by the FDA in August for treating type 1 narcolepsy, a form where the sleep symptoms are accompanied by a sudden loss of voluntary control tone known as cataplexy.

FDA 64

FDA 64

ISPE

NOVEMBER 23, 2022

Some of the highlights of the presentations given during the Symposium were as follows: The PIC/S Chairperson, Paul Gustafson, Health Canada, presented on PIC/S’ new strategic plan for 2023-2027 which covered the following elements: Promote, improve and monitor inspection reliance amongst PIC/S member authorities.

Documentation 98

Documentation FDA Communication 98

The FDA Law Blog

AUGUST 23, 2023

This blog provides an update on the DHT-related PDUFA VII goals that were targeted for completion in the first two quarters of FDA’s Fiscal Year (FY) 2023, including: By the end of Q2 FY 2023, FDA will establish a DHT framework document to guide the use of DHT-derived data in regulatory decision-makings for drugs and biological products.

FDA 52

FDA Documentation 52

pharmaphorum

FEBRUARY 2, 2022

Along with the one-off settlement, Gilead has agreed to pay ViiV a 3% royalty rate on Biktarvy sales and any other bictegravir-containing product in the US until 5 October 2027, when ViiV’s US patent on dolutegravir expires.

Compounding 72

Compounding FDA 72

Roots Analysis

OCTOBER 4, 2023

During the research, I noticed a significant increase in the number of FDA approvals for bispecific antibodies in recent years. This allows them to potentially be more effective in treating diseases by targeting multiple pathways simultaneously. I, recently, worked on a market research report, titled Bispecific Antibodies Market , 2023-2035.

Chemotherapy 40

Chemotherapy Immunization FDA 40

The Checkup by Singlecare

AUGUST 20, 2024

Currently, there is no generic version of Stiolto Respimat approved by the Food and Drug Administration (FDA). However, the earliest the patent for the brand name may expire is 2027 , after which a generic version may come to the market. In addition, any potential generic must go through rigorous testing.

Insurance 98

Insurance Insurance Coverage Health Insurance Companies FDA 98

pharmaphorum

MARCH 11, 2022

Qulipta was approved by the FDA last September for the preventive treatment of episodic migraine, a few months later than its main rival in the oral CGRP category, Biohaven’s Nurtec ODT (rimegepant), got a green light for the same indication. billion by 2027.

Labelling 52

Labelling FDA 52

pharmaphorum

JANUARY 13, 2021

Spry’s Loop System wearable has already been approved by the FDA for the collection of physiological data like oxygen levels, respiration and heart rate in patients with chronic obstructive pulmonary disease (COPD) and other chronic health conditions. The condition affects around 54 million people in the US alone.

FDA 59

FDA 59

pharmaphorum

JULY 18, 2022

It had expected the drug would not face biosimilar competition in Europe until at least 2027. The subcutaneous version was approved in the EU and UK last year but didn’t make it past the FDA in the US, which said it was unable to give it the green light in a complete response letter sent to Biogen in May.

FDA 52

FDA 52

pharmaphorum

JUNE 26, 2025

RemeGen already has approval in China for telitacicept as a treatment for generalised myasthenia gravis (gMG), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA), and has been advanced into a phase 3 trial in the US, Europe, and South America in gMG with results due in 2027.

Pharmaceutical Companies 83

Pharmaceutical Companies Pharmaceutical Companies FDA 83

pharmaphorum

OCTOBER 6, 2022

On the plus side, the time that tirzepatide will stay under review at the FDA has just got shorter, as the FDA has granted the drug fast-track review that means it should make a decision within six months of the filing being completed.

FDA 52

FDA 52

pharmaphorum

JANUARY 9, 2023

FDA approval in this indication would unlock the additional $10 CVR payment, providing it takes place before the end of 2027. BA is the leading cause of liver transplant in children and is caused by damaged or absent bile ducts, leading to build-up of bile in the liver and cirrhosis.

FDA 52

FDA 52

pharmaphorum

JULY 26, 2022

It had expected the drug would not face biosimilar competition in Europe until at least 2027. Biogen has been attempting to defend its franchise with a subcutaneous formulation given once a month, which was approved in the EU and UK last year but hasn’t yet made it past the FDA in the US.

FDA 52

FDA 52

pharmaphorum

JULY 18, 2022

Last month, the drugmaker reported new data with atogepant in prevention of chronic migraine – defined by the FDA as having at least 15 migraine days per month for at least three months – that AbbVie has suggested could help it differentiate atogepant from its rival.

FDA 52

FDA 52

pharmaphorum

APRIL 5, 2022

Leqvio meanwhile is only just getting started after a delayed FDA approval at the end of last year, although it has been available in Europe for a few months longer. billion in sales by 2027, ahead of Repatha at $2.2 Nevertheless, analysts at GlobalData recently predicted that Novartis’ drug would make $2.5

FDA 52

FDA 52